Bisphosphonates in the Treatment of Myeloma Bone Disease

2010 ◽  
pp. 117-132
Author(s):  
James R. Berenson
Keyword(s):  
Bone Disease ◽  
Myeloma Bone Disease

Involvement of LIGHT in multiple myeloma bone disease

2014 ◽  
Author(s):  
Angela Oranger ◽  
Giacomina Brunetti ◽  
Giorgio Mori ◽  
Claudia Carbone ◽  
Isabella Gigante ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Disease ◽  
Myeloma Bone Disease

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

2016 ◽  
Author(s):  
Michelle McDonald ◽  
Michaela Reagan ◽  
Rachael Terry ◽  
Jessica Pettitt ◽  
Lawrence Le ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Disease ◽  
Tumour Burden ◽  
Myeloma Bone Disease

scholarly journals Myeloma Bone Disease

2009 ◽  
Vol 24 (11) ◽  
pp. 1783-1788 ◽  
Author(s):  
Ralph D Sanderson ◽  
Joshua Epstein
Keyword(s):  
Bone Disease ◽  
Myeloma Bone Disease

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels are Associated with Multiple Myeloma Bone Disease

2015 ◽  
Vol 15 ◽  
pp. e231
Author(s):  
M. Westrin ◽  
S.H. Moen ◽  
T. Holien ◽  
O.E. Olsen ◽  
A.K. Mylin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Disease ◽  
Osteoclast Differentiation ◽  
High Serum ◽  
Myeloma Bone Disease

scholarly journals Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

Pharmaceutics ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 202 ◽  
Author(s):  
Sonia Vallet ◽  
Julia-Marie Filzmoser ◽  
Martin Pecherstorfer ◽  
Klaus Podar
Keyword(s):  
Bone Disease ◽  
Molecular Mechanisms ◽  
Bone Fractures ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Nf Kappa B ◽  
Skeletal Involvement ◽  
Myeloma Bone Disease ◽  
Skeletal Related Events ◽  
Novel Treatment Strategies

Bone disease, including osteolytic lesions and/or osteoporosis, is a common feature of multiple myeloma (MM). The consequences of skeletal involvement are severe pain, spinal cord compressions, and bone fractures, which have a dramatic impact on patients’ quality of life and, ultimately, survival. During the past few years, several landmark studies significantly enhanced our insight into MM bone disease (MBD) by identifying molecular mechanisms leading to increased bone resorption due to osteoclast activation, and decreased bone formation by osteoblast inhibition. Bisphosphonates were the mainstay to prevent skeletal-related events in MM for almost two decades. Excitingly, the most recent approval of the receptor activator of NF-kappa B ligand (RANKL) inhibitor, denosumab, expanded treatment options for MBD, for patients with compromised renal function, in particular. In addition, several other bone-targeting agents, including bone anabolic drugs, are currently in preclinical and early clinical assessment. This review summarizes our up-to-date knowledge on the pathogenesis of MBD and discusses novel state-of-the-art treatment strategies that are likely to enter clinical practice in the near future.

Myeloma bone disease

2001 ◽  
Vol 38 (3) ◽  
pp. 276-285 ◽  
Author(s):  
Natalie S Callander ◽  
G.David Roodman
Keyword(s):  
Bone Disease ◽  
Myeloma Bone Disease

Myeloma Bone Disease

2004 ◽  
pp. 251-279
Author(s):  
James R. Berenson
Keyword(s):  
Bone Disease ◽  
Myeloma Bone Disease
Sign in / Sign up

Export Citation Format

Share Document